SG158073A1 - Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy - Google Patents

Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy

Info

Publication number
SG158073A1
SG158073A1 SG200907712-4A SG2009077124A SG158073A1 SG 158073 A1 SG158073 A1 SG 158073A1 SG 2009077124 A SG2009077124 A SG 2009077124A SG 158073 A1 SG158073 A1 SG 158073A1
Authority
SG
Singapore
Prior art keywords
phenylbutyrate
phenylacetate
ornithine
hepatic encephalopathy
compositions
Prior art date
Application number
SG200907712-4A
Other languages
English (en)
Inventor
Rajiv Jalan
Kamal Nayan Jalan
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426142A external-priority patent/GB0426142D0/en
Priority claimed from GB0426141A external-priority patent/GB0426141D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of SG158073A1 publication Critical patent/SG158073A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200907712-4A 2004-11-26 2005-11-28 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy SG158073A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0426142A GB0426142D0 (en) 2004-11-26 2004-11-26 Formulation
GB0426141A GB0426141D0 (en) 2004-11-26 2004-11-26 Treatment

Publications (1)

Publication Number Publication Date
SG158073A1 true SG158073A1 (en) 2010-01-29

Family

ID=35559327

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907712-4A SG158073A1 (en) 2004-11-26 2005-11-28 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy

Country Status (23)

Country Link
US (3) US8389576B2 (sv)
EP (3) EP1824563B1 (sv)
JP (2) JP5116479B2 (sv)
KR (1) KR101380446B1 (sv)
CN (1) CN102512408B (sv)
AT (1) ATE457187T1 (sv)
AU (1) AU2005308622B2 (sv)
CA (1) CA2589261C (sv)
CY (3) CY1112259T1 (sv)
DE (1) DE602005019319D1 (sv)
DK (3) DK2153870T3 (sv)
EA (2) EA018007B1 (sv)
ES (3) ES2537974T3 (sv)
HK (1) HK1141471A1 (sv)
IL (1) IL183401A (sv)
MX (1) MX2007006171A (sv)
NO (2) NO342198B1 (sv)
NZ (1) NZ555870A (sv)
PL (3) PL1824563T3 (sv)
PT (3) PT2153870E (sv)
SG (1) SG158073A1 (sv)
SI (3) SI2153870T1 (sv)
WO (1) WO2006056794A1 (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005019319D1 (de) 2004-11-26 2010-03-25 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
CA2735218A1 (en) * 2008-04-29 2009-11-05 Ucyclyd Pharma, Inc. Methods of treatment using ammonia-scavenging drugs
US20120022157A1 (en) * 2008-08-29 2012-01-26 Ucyclyd Pharma, Inc Dosing and monitoring patients on nitrogen-scavenging drugs
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
HUE065491T2 (hu) 2008-10-02 2024-05-28 Salix Pharmaceuticals Ltd A hepatikus enkefalopátia kezelése rifaximin alkalmazásával
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
MX2011013129A (es) * 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
EP3263102A1 (en) * 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
CN104797272A (zh) 2012-11-21 2015-07-22 海波龙治疗公司 施用及评价用于治疗肝性脑病的氮清除药物的方法
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20150094278A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
DK3099306T3 (en) 2014-01-29 2019-03-18 Umecrine Cognition Ab STEROID RELATIONSHIP TO USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
MX2017006685A (es) 2014-11-24 2018-01-15 Ucl Business Plc Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco.
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
CA2983146C (en) 2015-04-20 2023-09-12 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
AU2016325556B2 (en) * 2015-09-25 2023-02-16 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
WO2017090007A1 (en) * 2015-11-29 2017-06-01 Rao M Surya Compositions and methods for the treatment of urea cycle disorders and hepatic diseases
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
CN110709072A (zh) * 2017-06-07 2020-01-17 花王株式会社 氨代谢促进剂
WO2018225167A1 (ja) 2017-06-07 2018-12-13 花王株式会社 アンモニア代謝促進剤
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
JP7197340B2 (ja) * 2018-12-06 2022-12-27 花王株式会社 認知機能改善剤
CN113713817B (zh) * 2020-05-26 2023-06-27 中国科学院大连化学物理研究所 一种采用镍基催化剂催化丙醛加氢制正丙醇的方法
WO2022119784A1 (en) * 2020-12-01 2022-06-09 Wellstat Therapeutics Corporation 5'-o-phenylacetyluridine and therapeutic use

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE380814A (sv) * 1930-06-26
US1980422A (en) * 1931-09-30 1934-11-13 Mesick John Plotting board
US2271378A (en) * 1939-08-30 1942-01-27 Du Pont Pest control
US2273780A (en) * 1939-12-30 1942-02-17 Du Pont Wax acryalte ester blends
US2261002A (en) * 1941-06-17 1941-10-28 Du Pont Organic nitrogen compounds
US2388614A (en) * 1942-05-05 1945-11-06 Du Pont Disinfectant compositions
US2375853A (en) * 1942-10-07 1945-05-15 Du Pont Diamine derivatives
US2454547A (en) * 1946-10-15 1948-11-23 Rohm & Haas Polymeric quaternary ammonium salts
US2723248A (en) * 1954-10-01 1955-11-08 Gen Aniline & Film Corp Film-forming compositions
US2961347A (en) * 1957-11-13 1960-11-22 Hercules Powder Co Ltd Process for preventing shrinkage and felting of wool
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
US3227615A (en) * 1962-05-29 1966-01-04 Hercules Powder Co Ltd Process and composition for the permanent waving of hair
US3206462A (en) * 1962-10-31 1965-09-14 Dow Chemical Co Quaternary poly(oxyalkylene)alkylbis(diethylenetriamine) compounds
NL302572A (sv) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
US3256154A (en) * 1963-10-18 1966-06-14 Gillette Co Hair waving composition and method
FR1517743A (fr) * 1966-08-03 1968-03-22 Oreal Nouveaux copolymères et compositions cosmétiques contenant ces copolymères
US3472840A (en) * 1965-09-14 1969-10-14 Union Carbide Corp Quaternary nitrogen-containing cellulose ethers
US3810977A (en) * 1967-03-23 1974-05-14 Nat Starch Chem Corp Hair fixing composition and process containing a solid terpolymer
CH491153A (de) * 1967-09-28 1970-05-31 Sandoz Ag Verfahren zur Herstellung von neuen kationaktiven, wasserlöslichen Polyamiden
US3836537A (en) * 1970-10-07 1974-09-17 Minnesota Mining & Mfg Zwitterionic polymer hairsetting compositions and method of using same
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
LU64371A1 (sv) * 1971-11-29 1973-06-21
US4013787A (en) * 1971-11-29 1977-03-22 Societe Anonyme Dite: L'oreal Piperazine based polymer and hair treating composition containing the same
LU65552A1 (sv) * 1972-06-20 1973-12-27
CA981746A (en) * 1973-09-24 1976-01-13 Alfred M. Hase Battery charging circuit
US4172887A (en) * 1973-11-30 1979-10-30 L'oreal Hair conditioning compositions containing crosslinked polyaminopolyamides
US4277581A (en) * 1973-11-30 1981-07-07 L'oreal Polyamino-polyamide crosslinked with crosslinking agent
US4189468A (en) * 1973-11-30 1980-02-19 L'oreal Crosslinked polyamino-polyamide in hair conditioning compositions
US4025627A (en) * 1973-12-18 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US3874870A (en) * 1973-12-18 1975-04-01 Mill Master Onyx Corp Microbiocidal polymeric quarternary ammonium compounds
US3929990A (en) * 1973-12-18 1975-12-30 Millmaster Onyx Corp Microbiocidal polymeric quaternary ammonium compounds
US4166894A (en) * 1974-01-25 1979-09-04 Calgon Corporation Functional ionene compositions and their use
DK659674A (sv) * 1974-01-25 1975-09-29 Calgon Corp
LU69760A1 (sv) * 1974-04-01 1976-03-17
LU69759A1 (sv) * 1974-04-01 1976-03-17
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US4217914A (en) * 1974-05-16 1980-08-19 L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US5196189A (en) * 1974-05-16 1993-03-23 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4422853A (en) * 1974-05-16 1983-12-27 L'oreal Hair dyeing compositions containing quaternized polymer
US4948579A (en) * 1974-05-16 1990-08-14 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4005193A (en) * 1974-08-07 1977-01-25 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US4026945A (en) * 1974-10-03 1977-05-31 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US4025617A (en) * 1974-10-03 1977-05-24 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US3966904A (en) * 1974-10-03 1976-06-29 Millmaster Onyx Corporation Quaternary ammonium co-polymers for controlling the proliferation of bacteria
US4001432A (en) * 1974-10-29 1977-01-04 Millmaster Onyx Corporation Method of inhibiting the growth of bacteria by the application thereto of capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4025653A (en) * 1975-04-07 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US4197865A (en) * 1975-07-04 1980-04-15 L'oreal Treating hair with quaternized polymers
AT365448B (de) * 1975-07-04 1982-01-11 Oreal Kosmetische zubereitung
DE2715297A1 (de) * 1976-04-06 1977-10-27 Oreal N-alkyl-acrylamid oder -methacrylamid- mischpolymerisate, verfahren zu deren herstellung und diese enthaltende kosmetische mittel
US4031307A (en) * 1976-05-03 1977-06-21 Celanese Corporation Cationic polygalactomannan compositions
GB1572837A (en) * 1976-05-06 1980-08-06 Berger Jenson & Nicholson Ltd Coating composition
US4128631A (en) * 1977-02-16 1978-12-05 General Mills Chemicals, Inc. Method of imparting lubricity to keratinous substrates and mucous membranes
LU78153A1 (fr) * 1977-09-20 1979-05-25 Oreal Compositions cosmetiques a base de polymeres polyammonium quaternaires et procede de preparation
US4131576A (en) * 1977-12-15 1978-12-26 National Starch And Chemical Corporation Process for the preparation of graft copolymers of a water soluble monomer and polysaccharide employing a two-phase reaction system
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4970066A (en) * 1978-06-15 1990-11-13 L'oreal Hair dye or bleach supports of quaternized polymers
US4348202A (en) * 1978-06-15 1982-09-07 L'oreal Hair dye or bleach supports
FR2439798A1 (fr) * 1978-10-27 1980-05-23 Oreal Nouveaux copolymeres utilisables en cosmetique, notamment dans des laques et lotions de mises en plis
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
LU83349A1 (fr) * 1981-05-08 1983-03-24 Oreal Composition sous forme de mousse aerosol a base de polymere cationique et de polymere anionique
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
LU84463A1 (fr) * 1982-11-10 1984-06-13 Oreal Polymeres polysiloxanes polyquaternaires
LU84708A1 (fr) * 1983-03-23 1984-11-14 Oreal Composition epaissie ou gelifiee de conditionnement des cheveux contenant au moins un polymere cationique,au moins un polymere anionique et au moins une gomme de xanthane
US4812307A (en) * 1983-07-06 1989-03-14 Chesebrough-Pond's Inc. Crosslinking of hair thiols using glutathione disulfide
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0269107A3 (en) * 1986-11-28 1989-10-11 Kao Corporation Composition for hair treatment agent
US4749732A (en) * 1987-01-02 1988-06-07 Dow Corning Corporation Hair care composition containing modified aminoalkyl substituted polydiorganosiloxane
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
US4795629A (en) * 1987-07-06 1989-01-03 Chesebrough-Pond's Inc. Crosslinking of hair thiols using cystamine
LU87310A1 (fr) * 1988-08-04 1990-03-13 Oreal N-(mercaptoalkyl)omega-hydroxyalkylamides et leur utilisation en tant qu'agents reducteurs,dans un procede de deformation permanente des cheveux
FR2654617B1 (fr) * 1989-11-20 1993-10-08 Oreal Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux.
US5591613A (en) * 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (sv) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) * 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
FR2676441B1 (fr) * 1991-05-17 1994-10-28 Oreal Nouveaux alkylamino-mercaptoalkylamides ou l'un de leurs sels cosmetiquement acceptables, et leur utilisation en tant qu'agents reducteurs, dans un procede de deformation permanente des cheveux.
FR2677543B1 (fr) * 1991-06-13 1993-09-24 Oreal Composition cosmetique filtrante a base d'acide benzene 1,4-di(3-methylidene-10-camphosulfonique) et de nanopigments d'oxydes metalliques.
US5767086A (en) * 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
AU4778700A (en) 1999-05-21 2000-12-12 Takeda Chemical Industries Ltd. Liver function controlling agents
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
ATE441409T1 (de) 2001-03-15 2009-09-15 Riken Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) * 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) * 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
EP1541141A1 (en) 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
KR20110124317A (ko) 2004-05-06 2011-11-16 오스테올로지스 에이에스 금속 유기 염의 제조를 위한 고 수율 및 고속 합성 방법
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
GB0426141D0 (en) 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
DE602005019319D1 (de) 2004-11-26 2010-03-25 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
JP5221858B2 (ja) 2006-08-30 2013-06-26 株式会社日立ハイテクノロジーズ 欠陥検査装置、及び欠陥検査方法
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CA2983146C (en) 2015-04-20 2023-09-12 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
ES2537974T3 (es) 2015-06-16
PT2153870E (pt) 2014-03-12
KR101380446B1 (ko) 2014-04-01
DK2319581T3 (en) 2015-06-01
EA018007B1 (ru) 2013-04-30
SI1824563T1 (sl) 2010-07-30
EP1824563B1 (en) 2010-02-10
US8389576B2 (en) 2013-03-05
SI2153870T1 (sl) 2014-05-30
PL1824563T3 (pl) 2010-07-30
ATE457187T1 (de) 2010-02-15
PT1824563E (pt) 2010-05-17
EA200900105A1 (ru) 2009-08-28
AU2005308622A1 (en) 2006-06-01
AU2005308622B2 (en) 2012-08-02
NO20073254L (no) 2007-08-23
NZ555870A (en) 2009-09-25
EA200701146A1 (ru) 2008-02-28
JP5116479B2 (ja) 2013-01-09
US20120259016A1 (en) 2012-10-11
CN102512408A (zh) 2012-06-27
ES2341120T3 (es) 2010-06-15
EP2319581A1 (en) 2011-05-11
NO20161808A1 (no) 2016-11-16
US20080119554A1 (en) 2008-05-22
CA2589261C (en) 2014-07-08
EP2153870A1 (en) 2010-02-17
HK1141471A1 (en) 2010-11-12
DE602005019319D1 (de) 2010-03-25
US10610506B2 (en) 2020-04-07
KR20070100721A (ko) 2007-10-11
SI2319581T1 (sl) 2015-10-30
EA011716B1 (ru) 2009-04-28
ES2448549T3 (es) 2014-03-14
DK1824563T3 (da) 2010-05-31
CY1116314T1 (el) 2017-02-08
EP1824563A1 (en) 2007-08-29
CN102512408B (zh) 2015-11-25
JP5612030B2 (ja) 2014-10-22
JP2012246294A (ja) 2012-12-13
IL183401A (en) 2013-09-30
PL2319581T3 (pl) 2015-10-30
DK2153870T3 (en) 2014-03-10
EP2153870B1 (en) 2013-12-25
MX2007006171A (es) 2007-10-08
PL2153870T3 (pl) 2014-05-30
CY1114979T1 (el) 2016-12-14
WO2006056794A1 (en) 2006-06-01
PT2319581E (pt) 2015-06-30
NO341491B1 (no) 2017-11-27
IL183401A0 (en) 2007-10-31
CA2589261A1 (en) 2006-06-01
US20170189364A1 (en) 2017-07-06
EP2319581B1 (en) 2015-02-25
JP2008521784A (ja) 2008-06-26
NO342198B1 (no) 2018-04-16
CY1112259T1 (el) 2015-12-09
US9566257B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
SG158073A1 (en) Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
MY155299A (en) Oral dosage composition
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
CA2767833C (en) N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
TW200730190A (en) New combination to treat liver fibrosis
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
RS54185B1 (en) USE OF 24-ORDER
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
IT1398773B1 (it) Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico.
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
TN2009000044A1 (en) Crystal form of epothilone b and use in pharmaceutical compositions
TW200730181A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
TW200615000A (en) Use of arginase for the treatment of hepatitis
TW200612980A (en) Use of soluble CD26 as inhibitor of angiogenesis and inflammation
AU2007904328A0 (en) The use of poloxamer 407 and other agents acting on the liver sinusoidal endothelial cell for treatment and prevention of chemical-induced liver injury including paracetamol overdose
AU309859S (en) Floorlamp
WO2007092465A3 (en) Topical delivery compositions
GEP20094741B (en) New association between agomelatine and thymoregulator and the pharmaceutical compositions that contain it